Clinical trials: Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
- Trial name
- NCT06116916
- Testing
- KHK4951, Aflibercept Injection
- Where
- 87 sites in United States, Australia and 2 more
- Volunteers
- 185 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema
This study will evaluate which of the three following treatment options is better for diabetic macular edema: laser alone, steroid injection alone, or steroid injection followed by laser.
- Trial name
- NCT00231023
- Testing
- Peribulbar Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision. It is also a leading cause of visual decline in younger patients, especially in developing countries like our Arab community.
- Trial name
- DME (NCT04087746)
- Testing
- Aflibercept, Ranibizumab
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Minia University
Visual Impairment Due to Diabetic Macular Edema
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.
- Trial name
- TIDE DME (NCT02878681)
- Testing
- Ranibizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
4D-150 in Patients With Diabetic Macular Edema
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
- Trial name
- NCT05930561
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- 4D Molecular Therapeutics
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME).
- Trial name
- ALTITUDE® (NCT04567550)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- AbbVie
Diabetes With Diabetic Retinopathy With Macular Edema
International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients
The purpose of this research is to evaluate the effectiveness of vitrectomy for the treatment of diabetic macular edema. Diabetes is known to cause retinal blood vessels to leak, leading to swelling of the central retina…
- Trial name
- ICV-DME (NCT02639507)
- Testing
- Vitrectomy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
nAMD, DME
Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME
The goal of this multicentre observational study is to evaluate the interval-extension potential, effectiveness, and safety of intravitreal aflibercept 8 mg in pretreated eyes with neovascular age-related macular degeneration…
- Trial name
- ALLEVI8 (NCT07761039)
- Testing
- Aflibercept 8mg
- Volunteers
- 100 people
- Sponsor
- Grupo de Estudos da Retina
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Wet Age Related Macular Degeneration, Diabetic Macular Edema
Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study
In this province, optometrists are often responsible for contacting the retinal specialists' office to arrange patients to be examined for suspected emergencies or more routine referrals related to the eye.
- Trial name
- NCT01899963
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- McMaster University
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)
A randomized, controlled study of the safety and efficacy of Squalamine Lactate Eye Drops in combination with Ranibizumab intravitreal injections in patients with diabetic macular edema.
- Trial name
- NCT02349516
- Testing
- Squalamine Lactate Ophthalmic Solution 0.2%
- Where
- United States
- Sponsor
- Starr Muscle
Diabetic Macular Edema
A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema
Establish the efficacy of initial high frequency loading of intravitreal pegaptanib bi-weekly during the initial treatment period when the VEGF levels are the greatest and then gradually extending the administration frequency to…
- Trial name
- GUARDIAN (NCT01487044)
- Testing
- Macugen (Pegaptanib Sodium)
- Where
- United States
- Sponsor
- Retina Institute of Hawaii
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema, Diabetic Retinopathy
Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME
The objective of this study is to test the hypothesis that following the use of intravitreal dexamethasone implant for the treatment of DME, there will be an observable increase in the capillary density plexus as denoted by the…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
- Trial name
- ICOD (NCT04038125)
- Testing
- Ozurdex Drug Implant Product
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Specialists of Miami, LLC
Diabetic Macular Edema
Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A
The goal of this clinical trial is to to evaluate the changes in retinal microvasculature secondary to intra-ocular pressure changes post intra-vitreal injection in patients with diabetic macular oedema highlighting the effect of…
- Trial name
- NCT05861466
- Testing
- intra-vitreal injection of Ranibizumab, anterior chamber paracentesis
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams University
Diabetic Macular Edema, DME
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
- Trial name
- NCT07199777
- Testing
- SNP318
- Volunteers
- 60 people
- Sponsor
- SciNeuro